Kiniksa Pharmaceuticals Ltd

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

KNSA$95.02-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


· · Years Ended
· · December 31,
· 2023 · · 2022 · · 2021
Cash flows from operating activities: · · · · · · ·
Net income (loss)	$14,084	$183,363	$(157,924)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization expense	2,341	2,402	2,355
Share-based compensation expense	27,149	25,120	25,173
Non-cash lease expense	3,054	3,041	2,631
Amortization (accretion) of discounts on short-term investments	(1,068)	(82)	664
Loss on disposal of property and equipment	179	33	103
Deferred income taxes	(33,788)	(185,495)	11
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(7,067)	(3,858)	2,941
Accounts receivable, net	(8,606)	(8,675)	(3,910)
Inventory	(9,523)	(17,924)	(3,675)
Contract asset	7,656	(7,656)	—
Other long-term assets	4,584	2,654	(3,284)
Accounts payable	347	6,031	1,366
Accrued expenses and other current liabilities	16,940	(3,709)	10,339
Operating lease liabilities	(3,261)	(3,007)	(2,553)
Deferred revenue	261	12,000	—
Other long-term liabilities	19	1,569	(535)
Net cash provided by (used in) operating activities	13,301	5,807	(126,298)
Cash flows from investing activities:
Proceeds from sale of property and equipment	—	91	—
Purchases of property and equipment	(130)	(105)	(415)
Purchases of short-term investments	(204,933)	(135,864)	(157,250)
Proceeds from the maturities of short-term investments	175,506	127,800	306,300
Intangible assets acquired	—	—	(20,000)
Net cash provided by (used in) investing activities	(29,557)	(8,078)	128,635
Cash flows from financing activities:
Proceeds from issuance of Class A common shares under incentive award plans and employee share purchase plan	3,701	3,417	5,885
Payments in connection with Common Stock tendered for employee tax obligations	(2,206)	(901)	—
Net cash provided by financing activities	1,495	2,516	5,885
Net increase (decrease) in cash, cash equivalents and restricted cash	(14,761)	245	8,222
Cash, cash equivalents and restricted cash at beginning of period	122,715	122,470	114,248
Cash, cash equivalents and restricted cash at end of period	$107,954	$122,715	$122,470

Supplemental information:
Cash paid for income taxes, net	$5,605	$10,689	$1,279

Supplemental disclosure of non-cash investing and financing activities:
Change in right-of-use asset as a result of new, modified, and terminated leases	$9,600	$2,876	$1,619
Additions to property and equipment included in accrued expenses and other liabilities	$54	$—	$—

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.